(Q53161184)

English

Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.

scientific article published on 5 January 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

1 reference

based on heuristic

inferred from title

Rodney J. Hicks

10

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

object named as

Bernard M Fine

9

0 references

Linda Mileshkin

5

object named as

Linda Mileshkin

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

Andrea Pirzkall

2

object named as

Andrea Pirzkall

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

author name string

David S Binns

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

Wei Yu

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

Jason Callahan

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

Peter Conti

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

Andrew M Scott

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

David Macfarlane

8

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

OSI3926g Study Team

11

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

publication date

5 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

38

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

642-650

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1665-0

21 January 2018

Reproducibility of metabolic measurements in malignant tumors using FDG PET

1 reference

https://pubmed.ncbi.nlm.nih.gov/21207024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21207024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21207024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/21207024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21207024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-010-1665-0

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21207024

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53161184&oldid=2249128374"